Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cangrelor safety and pharmacodynamics in children with congenital heart disease undergoing percutaneous vascular procedures
NL-OMON61238Phase 3Not yet recruiting
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cangrelor in Cardiovascular Malformation (CVM), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Bleeding events within 72 hours, Hemoderivative transfusion related to cangrelor and 6 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cangrelor
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on NL-OMON61238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61238.